Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp alfa plus FLOT as neoadjuvant therapy for resectable esophagogastric junction adenocarcinoma
ChiCTR2600123280Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa in gastroesophageal adenocarcinoma, sponsored by Xijing Hospital. Primary endpoint: Pathological complete response rate (pCR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600123280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123280.